Transapical Myectomy to Enlarge the LV Cavity


About this study

The purpose of this study is to summarize the clinical, morphological, and pathological features of patients with hypertrophic cardiomyopathy (HCM) and end systolic cavity obliteration, to describe the surgical technique of enlarging the left ventricular (LV) cavity through the transapical approach to myectomy, to compare patients’ hemodynamic alterations before and after transapical septal myectomy, to assess patients’ functional recovery after apical myectomy, and to evaluate the survival rate of these targeted surgical patients.




Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults, ≥ 18 years of age.
  • Patients who were diagnosed with hypertrophic cardiomyopathy with systolic cavity obliteration and underwent transapical septal myectomy to enlarge the left ventricular (LV) cavity.

Exclusion Criteria:

  • Individuals < 18 years of age.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Hartzell Schaff, M.D.

Open for enrollment

Contact information:

Hartzell Schaff M.D.

(507) 255-7068

More information


Publications are currently not available

Mayo Clinic Footer